Trial Information

Summary: National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies

ZK-Epo is an Epothilone, a new class of chemotherapy, that has demonstrated activity against breast cancer and other tumor types in pre-clinical studies.

To date, ZK-Epo has been given to more than 200 cancer patients. These patients have been enrolled in studies of solid tumor cancers such as breast cancer, ovarian cancer, prostate, non-small cell lung cancer, and head and neck cancers.

Participants in this study must have active breast cancer, a measurable lesion, and have received no more than 3 prior regimens of chemotherapy.

Eligible participants will have previously received both an anthracycline and a taxane in the past to treat their breast cancer.

The study will involve approximately 65 patients at 30 participating sites across the US and Canada. All eligible patients will receive active study drug. The study drug will be given every 3 weeks for up to 18 weeks. All patients will be asked to return to the clinic every week while they are receiving study drug and then monthly for 3 months after their last dose of study drug.

Patients entered in the clinical trial will receive trial-related medical care and study drug at no charge.

Patients must meet the following criteria to enroll in this study:

• Women, 18 years of age or older
• Have metastatic breast cancer with a measurable tumor
• Have progressive disease following previous chemotherapy
• Have had no more than 3 prior regimens of chemotherapy
• Able to conduct normal daily activities
• Not currently pregnant or breastfeeding

Call Center : 1-877-919-5376, or log on to www.breast.zkepo.com

For more information,

If you would like to learn more about participating in this study, please send an e-mail message using the form below.